Biofil Chemicals & Pharmaceuticals Limited — Important, 14-11-2024: Financial Result Updates

**Consolidated Financials**: Biofil Chemicals and Pharmaceuticals Limited reported its unaudited financial results for the quarter and half-year ended 30th September 2024.

**Revenue Growth**: The company recorded a total revenue of ₹1,370.56 crore, marking a notable growth of 11.9% compared to ₹1,225.32 crore in the previous year. Key drivers include increased demand in both the chemicals and pharmaceuticals segments, alongside effective market expansion strategies.

**Profit and EPS**: Net profit for the period stood at ₹19.37 crore, compared to ₹36.70 crore in the same period last year, indicating a decline of 47.3%. The Earnings Per Share (EPS) was reported at ₹0.01, down from ₹0.10 year-on-year. This drop in profitability can be attributed to rising operational costs and the impact of inventory adjustments.

**Operational Costs**: Operational costs increased by 45% year-over-year. Contributing factors include escalated costs in raw materials and labor, underscoring challenges in cost management amidst higher operational demands.

**Balance Sheet & Cash Flow Statement**: Total assets as of 30th September 2024 amounted to ₹4,204.01 crore, while total liabilities were ₹2,364.36 crore, indicating a sound equity base. However, net cash generated from operating activities was negative at ₹205.99 crore, primarily due to significant fluctuations in working capital.

**Strategic Position and Outlook**: The management is likely to focus on optimizing cost efficiency and further strengthening its market position in the pharma segment. The current market sentiment reflects a cautious outlook given the profit decline but recognizes the potential for recovery with strategic cost management.

**Investor Insight**: Given the robust revenue growth despite profitability challenges, a hold strategy may be advisable while closely monitoring cost management initiatives and market trends for recovery signals.